Caribou Gets FDA Fast-Track Designation for CB-011 in Multiple Myeloma
April 04 2023 - 8:58AM
Dow Jones News
By Colin Kellaher
Caribou Biosciences Inc. on Tuesday said the U.S. Food and Drug
Administration granted fast-track designation to CB-011, in
development for relapsed or refractory multiple myeloma.
The Berkeley, Calif., clinical-stage biopharmaceutical company
said it recently dosed its first patient in a Phase 1 study of
CB-011 in patients with the fatal blood cancer.
The FDA's fast-track program is designed to facilitate the
development and expedite the review of treatments for serious or
potentially life-threatening illnesses with high unmet medical
needs.
CB-011 is the second product candidate from Caribou's allogeneic
CAR-T cell-therapy platform.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 04, 2023 08:43 ET (12:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024
